OncoMatch/Clinical Trials/NCT05933265
Study of LP-184 in Patients With Advanced Solid Tumors
Is NCT05933265 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LP-184 and Spironolactone for advanced solid tumor.
Treatment: LP-184 · Spironolactone · Olaparib — The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Glioblastoma
Triple-Negative Breast Cancer
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Biomarker criteria
Allowed: PTGR1 overexpression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
advanced solid tumor that has relapsed from or is refractory to standard treatment, or for which no standard treatment is available
Cannot have received: anti-cancer therapy
Exception: Low dose steroids (oral prednisone or equivalent ≤20 mg/day, except patients with GBM), localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion if such therapy has not been changed within 4 weeks before LP-184 treatment.
Exposure to anti-cancer therapy within 2 weeks or within at least 5 half-lives of the anticancer agent whichever is shorter; or 4 weeks from any biologics/immunotherapies or any investigational therapy prior to the first dose of LP-184.
Cannot have received: radiation therapy
Exception: Unless the tumor at the site of treatment continues to increase in size after the patient has completed radiotherapy treatment.
Has received radiation within 4 weeks of Cycle 1 Day 1. Unless the tumor at the site of treatment continues to increase in size after the patient has completed radiotherapy treatment.
Lab requirements
Blood counts
anc ≥1500/μl. hemoglobin ≥8 g/dl (the use of transfusion or other intervention to achieve hemoglobin ≥8 g/dl is acceptable. for those patients undergoing rbc transfusion, hemoglobin must be evaluated at least 14 days after the last rbc transfusion). platelet count ≥100,000/μl (assessed ≥7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets).
Kidney function
serum creatinine clearance ≥60 ml/min either measured or calculated using standard cockcroft-gault formula. serum electrolyte (potassium, calcium, and magnesium) levels within the normal reference range (may be supplemented according to institutional standard).
Liver function
ast, alt ≤3 x uln or <5 x uln in cases of documented liver metastases or involvement of liver in the disease process. total serum bilirubin ≤1.5 x uln or <5 x uln if secondary to gilbert's syndrome or documented liver metastases or involvement of liver in the disease process.
Cardiac function
inr and aptt ≤1.5 x uln. study patients on therapeutic doses of anticoagulation medication must have inr and/or aptt ≤ the upper limit of the therapeutic range for intended use.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Highlands Oncology Group · Springdale, Arkansas
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- Northwest Oncology & Hematology · Rolling Meadows, Illinois
- Indiana University Melvin and Bren Simon Cancer Center · Indianapolis, Indiana
- Norton Healthcare, Inc. · Louisville, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify